NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (NASDAQGM:KBIO) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On December 17, 2015, news outlets reported that Martin Shkreli, the CEO of KaloBios, was arrested on securities fraud charges relating to his illegal use of stock from Retrophin Inc. to pay off debts associated with other unrelated business ventures. On this news, KaloBios shares plummeted pre-market, and trading has since been halted. To obtain additional information about the investigation, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.